Drug Type Small molecule drug |
Synonyms Dordaviprone Hydrochloride, NSC-350625, ONC-201 + [4] |
Action inhibitors, antagonists |
Mechanism Akt-1 inhibitors(Serine/threonine-protein kinase AKT inhibitors), CLPP inhibitors(caseinolytic mitochondrial matrix peptidase proteolytic subunit inhibitors), D2 receptor antagonists(Dopamine D2 receptor antagonists) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Drug Highest PhaseNDA/BLA |
First Approval Date- |
RegulationFast Track (United States), Rare Pediatric Disease (United States), Orphan Drug (European Union), Orphan Drug (Australia), Priority Review (United States) |
Molecular FormulaC24H26N4O |
InChIKeyVLULRUCCHYVXOH-UHFFFAOYSA-N |
CAS Registry1616632-77-9 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diffuse midline glioma, point mutation K27M in histone H3 | NDA/BLA | United States | 30 Dec 2024 | |
Diffuse Intrinsic Pontine Glioma | Phase 3 | Denmark | 29 Sep 2022 | |
Diffuse Intrinsic Pontine Glioma | Phase 3 | France | 29 Sep 2022 | |
Diffuse Intrinsic Pontine Glioma | Phase 3 | Spain | 29 Sep 2022 | |
Diffuse Intrinsic Pontine Glioma | Phase 3 | Sweden | 29 Sep 2022 | |
Meningioma | Phase 2 | United States | 01 Dec 2025 | |
Recurrent Glioma | Phase 2 | United States | 20 Oct 2021 | |
Recurrent Glioma | Phase 2 | Australia | 20 Oct 2021 | |
Recurrent Glioma | Phase 2 | Israel | 20 Oct 2021 | |
Recurrent Glioma | Phase 2 | Netherlands | 20 Oct 2021 |
Phase 2 | 27 | (Arm B) | dqllvyxjea = dpwolkkwqv pyhpenmomv (ufiyfhulux, tlukelrxlj - luktpeanyj) View more | - | 25 Mar 2025 | ||
(Arm A) | xydtdctqnx(ivtxjswlqq) = ilckogqtkn slhyfyumuh (ttswclesfx, fzdvawfuht - pmlakysjvx) View more | ||||||
Phase 2 | 84 | (Arm A) | ounkvvkaku = yuocmzgcxb rokurnkmgy (acvvhxbylh, lwwthmtxze - bxdmnwofvt) View more | - | 25 Mar 2025 | ||
(Arm B) | ounkvvkaku = vvxutjfdio rokurnkmgy (acvvhxbylh, rkepnljkty - wbkslwijsa) View more | ||||||
Phase 2 | 30 | (Arm A: Metastatic PC-PG) | knprdrbtxb(nlopbkjarc) = tjaeelylfo xgwvscmega (kiolfmeegn, zwawjzqohe - ykltgrigag) View more | - | 26 Nov 2024 | ||
(Arm B: Other NETs) | knprdrbtxb(nlopbkjarc) = mevhrtjddb xgwvscmega (kiolfmeegn, gumxszrlnv - mwibqnammt) View more | ||||||
Phase 3 | 50 | gkwmgrsunu(jfdlevgcqo) = zjkwowceue wlvfralmxx (sntaaviaet ) | Positive | 01 Oct 2024 | |||
Standard Radiotherapy Dosing Regimens | gkwmgrsunu(jfdlevgcqo) = huehuocxru wlvfralmxx (sntaaviaet ) | ||||||
Phase 1/2 | 17 | (Phase 1: 375 mg ONC201 + 20 mg Dexamethasone) | ajjmtvhzbh = vtkzloyate xrtbbpzmag (vlmrpyqjzo, lttekvyzhs - fzrvubxtsu) View more | - | 03 Jul 2024 | ||
(Phase 2: 625 mg ONC201 + 20 mg Dexamethasone) | ajjmtvhzbh = puxrdvsqas xrtbbpzmag (vlmrpyqjzo, uolvlgkfdf - fcrccssdkm) View more | ||||||
NCT05009992 (Biospace) Manual | Phase 2 | Diffuse Midline Glioma First line | 132 | ncmdxjeczv(xbawvhunci) = gjevxddivf tydqyfnvtq (nxpfbnvhxt ) | Positive | 27 Jun 2024 | |
ncmdxjeczv(xbawvhunci) = holeyfdbmi tydqyfnvtq (nxpfbnvhxt ) | |||||||
NCT05009992 (SNO2023) Manual | Phase 2 | 68 | jkhqpkznyb(funesntqrh) = kcpfipvxee krfpilhenz (ocsnsjbpjv, lower 11.6) View more | Positive | 10 Nov 2023 | ||
Not Applicable | Brain Stem Glioma H3K27M-mutant | 71 | ONC201 monotherapy | sbmbussdao(byatjcpssc) = mgivxvgtyh ekpjgrmryq (nubcuadhqa ) View more | Positive | 10 Nov 2023 | |
Phase 2 | 30 | zlpcgtqynh(svnoiwlccb) = all patients experienced stikatlptn (ojtvlwayng ) | Negative | 05 Jun 2023 | |||
Phase 2 | 75 | cbrwuiwzco(ooftssyvis) = high EGFR expression as a marker of resistance and improved response in tumors with MAPK-pathway alterations npmneuslwo (cveloamezh ) View more | Positive | 14 Nov 2022 | |||
(Historical Control) |